- Home
- HUBB vs BIIB Comparison
HUBB vs BIIB Comparison
Compare HUBB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUBB
- BIIB
- Stock Information
- Founded
- HUBB 1888
- BIIB 1978
- Country
- HUBB United States
- BIIB United States
- Employees
- HUBB N/A
- BIIB N/A
- Industry
- HUBB Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HUBB Technology
- BIIB Health Care
- Exchange
- HUBB Nasdaq
- BIIB Nasdaq
- Market Cap
- HUBB 20.9B
- BIIB 18.8B
- IPO Year
- HUBB N/A
- BIIB 1991
- Fundamental
- Price
- HUBB $412.92
- BIIB $130.13
- Analyst Decision
- HUBB Hold
- BIIB Buy
- Analyst Count
- HUBB 8
- BIIB 27
- Target Price
- HUBB $455.50
- BIIB $188.17
- AVG Volume (30 Days)
- HUBB 470.3K
- BIIB 1.2M
- Earning Date
- HUBB 07-29-2025
- BIIB 07-31-2025
- Dividend Yield
- HUBB 1.29%
- BIIB N/A
- EPS Growth
- HUBB 10.31
- BIIB 26.39
- EPS
- HUBB 14.79
- BIIB 10.12
- Revenue
- HUBB $5,594,600,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- HUBB $7.60
- BIIB N/A
- Revenue Next Year
- HUBB $5.93
- BIIB N/A
- P/E Ratio
- HUBB $27.71
- BIIB $12.85
- Revenue Growth
- HUBB 1.97
- BIIB 1.59
- 52 Week Low
- HUBB $299.43
- BIIB $110.04
- 52 Week High
- HUBB $481.35
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- HUBB 65.02
- BIIB 52.92
- Support Level
- HUBB $402.04
- BIIB $123.90
- Resistance Level
- HUBB $420.00
- BIIB $134.75
- Average True Range (ATR)
- HUBB 7.33
- BIIB 3.63
- MACD
- HUBB 0.97
- BIIB 0.25
- Stochastic Oscillator
- HUBB 79.23
- BIIB 59.97
About HUBB Hubbell Inc
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.